Gilead Sciences gets exclusive global license to develop, commercialize Xilio tumor-activated IL-12

Gilead Sciences has acquired an exclusive global license to develop and market Xilio’s tumor-activated IL-12 therapy. This partnership will allow Gilead to advance the development of this promising treatment for cancer. The agreement highlights Gilead’s commitment to expanding its portfolio of innovative therapies. The company’s use of cookies on its website for analytics and advertising purposes is also noted. Users are informed that by continuing to use the site, they are agreeing to the use of cookies and are directed to the Cookie Policy and Settings for more information.

Source link

error: Content is protected !!